B
Bettina Noerby
Publications - 5
Citations - 243
Bettina Noerby is an academic researcher. The author has contributed to research in topics: Enzalutamide & Prostate cancer. The author has an hindex of 3, co-authored 4 publications receiving 108 citations.
Papers
More filters
Journal ArticleDOI
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Cora N. Sternberg,Karim Fizazi,Fred Saad,N. Shore,Ugo De Giorgi,David F. Penson,Ubirajara Ferreira,Eleni Efstathiou,Katarzyna Madziarska,Michael Kolinsky,Daniel I.G. Cubero,Bettina Noerby,Fabian Zohren,Xun Lin,Katharina Modelska,Jennifer Sugg,Joyce Steinberg,Maha Hussain +17 more
TL;DR: Enzalutamide plus androgen-deprivation therapy resulted in longer median overall survival than placebo plus androgens-depRIvation therapy among men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising PSA level.
Journal ArticleDOI
Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).
Cora N. Sternberg,Karim Fizazi,Fred Saad,Neal D. Shore,Ugo De Giorgi,David F. Penson,Ubirajara Ferreira,Petro Ivashchenko,Eleni Efstathiou,Katarzyna Madziarska,Michael Kolinsky,Daniel de Iracema Gomes Cubero,Bettina Noerby,Fabian Zohren,Xun Lin,Katharina Modelska,Jennifer Sugg,Joyce Steinberg,Maha Hussain +18 more
TL;DR: Achievement in metastasis-free survival with PROSPER improves upon previous studies by at least 50% and up to 100% in women with previously undiagnosed breast cancer.
Journal ArticleDOI
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring
Fred Saad,Cora N. Sternberg,Eleni Efstathiou,Karim Fizazi,Katharina Modelska,Xun Lin,Jennifer Sugg,Joyce Steinberg,Bettina Noerby,Neal D. Shore,Maha Hussain +10 more
TL;DR: While PCWG2-defined PSA progression was associated with radiographic progression in enzalutamide-treated men, the findings argue for prospective re-evaluation of this threshold.
Journal ArticleDOI
Overall survival (OS) and metastasis-free survival (MFS) by depth of prostate-specific antigen (PSA) decline in the phase III PROSPER trial of men with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide (ENZA).
Maha Hussain,Cora N. Sternberg,Eleni Efstathiou,Karim Fizazi,Qi Shen,Xun Lin,Jennifer Sugg,Joyce Steinberg,Bettina Noerby,Ugo De Giorgi,Neal D. Shore,Fred Saad +11 more
TL;DR: The PROSPER trial demonstrated prolonged MFS and OS for men with nmCRPC and rapidly rising PSA treated with ENZA vs placebo, both in combination with androgen deprivation therapy (ADT)...
Journal ArticleDOI
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial
Maha Hussain,Cora N. Sternberg,Eleni Efstathiou,Karim Fizazi,Qi Shen,Xun Lin,Jennifer Sugg,Joyce Steinberg,Bettina Noerby,Ugo De Giorgi,Neal D. Shore,Fred Saad +11 more
TL;DR: In this paper , the authors evaluated the relationship between depth of PSA decline and clinical outcomes in enzalutamide-treated men with nonmetastatic castration-resistant prostate cancer.